“…The safety and efficacy of apremilast in psoriasis had been conducted in two multicenter, randomized, double blind, placebo-controlled trials, in which 31.7% apremilast patients achieved PASI75 versus 5.5% placebo patients at 16 weeks (Papp et al, 2015;Paul et al, 2015). Apremilast could be a potential choose for the nail psoriasis, scalp psoriasis, generalized pustular psoriasis, palmoplantar psoriasis, and erythrodermic psoriasis (Arcilla et al, 2016;Bissonnette et al, 2017;Jeon et al, 2017;Kushwaha, Repka, & Narasimha Murthy, 2017;Nguyen et al, 2016). There are only a case reported that apremilast was safe and efficacy for pediatric psoriasis (Smith, 2016), therefore, more evidence is expected.…”